LT2205720T - Kompozicijos išsėtinės sklerozės gydymui - Google Patents

Kompozicijos išsėtinės sklerozės gydymui

Info

Publication number
LT2205720T
LT2205720T LTEP08838676.8T LT08838676T LT2205720T LT 2205720 T LT2205720 T LT 2205720T LT 08838676 T LT08838676 T LT 08838676T LT 2205720 T LT2205720 T LT 2205720T
Authority
LT
Lithuania
Prior art keywords
compositions
multiple sclerosis
treating multiple
treating
sclerosis
Prior art date
Application number
LTEP08838676.8T
Other languages
English (en)
Inventor
Arnaud Foussat
Original Assignee
Txcell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/873,623 external-priority patent/US20090104142A1/en
Application filed by Txcell filed Critical Txcell
Publication of LT2205720T publication Critical patent/LT2205720T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEP08838676.8T 2007-10-17 2008-10-17 Kompozicijos išsėtinės sklerozės gydymui LT2205720T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07301475A EP2050814A1 (en) 2007-10-17 2007-10-17 Compositions for treating multiple sclerosis
US11/873,623 US20090104142A1 (en) 2007-10-17 2007-10-17 Compositions for treating multiple sclerosis
PCT/EP2008/064066 WO2009050283A1 (en) 2007-10-17 2008-10-17 Compositions for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
LT2205720T true LT2205720T (lt) 2017-03-27

Family

ID=40089903

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP08838676.8T LT2205720T (lt) 2007-10-17 2008-10-17 Kompozicijos išsėtinės sklerozės gydymui

Country Status (18)

Country Link
US (2) US9517253B2 (lt)
EP (2) EP2050814A1 (lt)
JP (2) JP2011500645A (lt)
KR (1) KR20100074286A (lt)
CN (1) CN101842478B (lt)
AU (1) AU2008313694B2 (lt)
CA (1) CA2702634C (lt)
CY (1) CY1118710T1 (lt)
DK (1) DK2205720T3 (lt)
ES (1) ES2618583T3 (lt)
HR (1) HRP20170353T1 (lt)
HU (1) HUE032066T2 (lt)
LT (1) LT2205720T (lt)
PL (1) PL2205720T3 (lt)
PT (1) PT2205720T (lt)
RU (1) RU2492234C2 (lt)
SI (1) SI2205720T1 (lt)
WO (1) WO2009050283A1 (lt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2429584A4 (en) * 2009-05-13 2013-02-20 Genzyme Corp TREATMENT PROCEDURE AND COMPOSITIONS
EP2378287A1 (en) * 2010-04-15 2011-10-19 TXCell New method for isolating Tr1 cells
EP2412802A1 (en) * 2010-07-29 2012-02-01 TXCell IL-13 producing TR1-like cells and use thereof
JP2014515258A (ja) * 2011-05-19 2014-06-30 ティゲニックス エス．エー．ユー 免疫調節活性を有する細胞集団、その調製方法、及び、その使用
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
GB201418433D0 (en) * 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
KR20180035852A (ko) * 2015-08-03 2018-04-06 노파르티스 아게 Fgf21-연관 장애를 치료하는 방법
RU2600160C1 (ru) * 2015-08-07 2016-10-20 Юрий Леонидович Шевченко Способ лечения рассеянного склероза и других системных аутоиммунных заболеваний
CN105254765A (zh) * 2015-10-10 2016-01-20 江汉大学 重组蛋白MOG35-55-I-Abβ1-α1及其基因和应用
WO2018078112A1 (en) * 2016-10-27 2018-05-03 Aarhus Universitet Glp-1 agonist (eg liraglutide) for use in the treatment of multiple sclerosis
JP7122002B2 (ja) * 2017-03-01 2022-08-19 国立大学法人北海道大学 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法
WO2018188730A1 (en) 2017-04-11 2018-10-18 Biontech Rna Pharmaceuticals Gmbh Rna for treatment of autoimmune diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008A (en) * 1845-04-22 Improvement w the manufacture of oil from resin
EP0587735B1 (en) 1991-05-31 2000-01-26 Connetics Corporation T cell receptor peptides as therapeutics for immune-related disease
US5874531A (en) * 1995-03-07 1999-02-23 President And Fellows Of Harvard College Identification of self and non-self antigens implicated autoimmune disease
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6746670B2 (en) 2000-08-15 2004-06-08 Schering Corporation Regulatory T cells; methods
US6670146B2 (en) 2000-10-04 2003-12-30 Schering Corporation Regulatory T cells; methods
US20040072222A1 (en) 2001-03-23 2004-04-15 John Matsoukas Peptide analogues of myelin basic protein epitopes in the treatment of experimental autoimmune encephalomyelitis (eae) and multiple sclerosis (ms)
FR2824567B1 (fr) 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
CN1705438A (zh) * 2002-06-14 2005-12-07 耶达研究及发展有限公司 用于神经保护和神经再生的抗原呈递细胞
FR2856700B1 (fr) 2003-06-24 2007-06-08 Txcell Procede d'identification de lymphocytes tr1 regulateurs par la presence et la surexpression de molecules specifiques et ses applications
NZ546552A (en) * 2003-10-17 2009-10-30 Baylor College Medicine A method for increasing CD8+ cytotoxic T cell reponses and for treating multiple sclerosis
AU2005302425A1 (en) * 2004-10-29 2006-05-11 Benaroya Research Institute At Virginia Mason Methods of generating antigen-specific CD4+CD25+ regulatory T cells, compositions and methods of use
EP1712615A1 (en) 2005-04-15 2006-10-18 Txcell In vitro production of a cell population using feeder cells
EP1739166B1 (en) * 2005-07-01 2011-06-22 TxCell S.A. Obtention of food- or auto-antigen specific Tr1 cells from a leukocyte or PBMC population

Also Published As

Publication number Publication date
CN101842478A (zh) 2010-09-22
HUE032066T2 (en) 2017-09-28
CN101842478B (zh) 2014-04-02
AU2008313694B2 (en) 2015-03-26
HRP20170353T1 (hr) 2017-05-05
CA2702634A1 (en) 2009-04-23
US20100221219A1 (en) 2010-09-02
DK2205720T3 (en) 2017-03-20
KR20100074286A (ko) 2010-07-01
EP2050814A1 (en) 2009-04-22
AU2008313694A1 (en) 2009-04-23
JP2011500645A (ja) 2011-01-06
ES2618583T3 (es) 2017-06-21
WO2009050283A1 (en) 2009-04-23
EP2205720A1 (en) 2010-07-14
PL2205720T3 (pl) 2017-06-30
JP2014221819A (ja) 2014-11-27
RU2010119505A (ru) 2011-11-27
US9517253B2 (en) 2016-12-13
PT2205720T (pt) 2017-03-13
US20170042992A1 (en) 2017-02-16
CA2702634C (en) 2017-06-13
SI2205720T1 (sl) 2017-04-26
CY1118710T1 (el) 2017-07-12
EP2205720B1 (en) 2016-12-14
RU2492234C2 (ru) 2013-09-10

Similar Documents

Publication Publication Date Title
HK1139204A1 (en) Compositions and uses for treating multiple sclerosis
PT2205720T (pt) Composições para tratamento de esclerose múltipla
ZA200908898B (en) Dentifruce compositions for treating xerostomia
EP2219637A4 (en) AVENANTHRAMIDE COMPOSITIONS
HUE059171T2 (hu) Kompozíciók
GB0724342D0 (en) Anitbacterial compositions
GB0711683D0 (en) Compositions
EP2282719A4 (en) COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS
GB0712024D0 (en) Compositions
EP2355660A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
IL248919A0 (en) Pediatric compounds for the treatment of multiple sclerosis
EP2174956A4 (en) COMPOSITIONS FOR ANTIFIBRINOLYSIS THERAPY
EP2214697A4 (en) COMPOSITIONS OF NELL-1
GB2447012B (en) Composition for combating epistaxis
GB0722030D0 (en) Compositions for treating tumours
GB0614058D0 (en) Treatment for multiple sclerosis
GB0700573D0 (en) Composition for treating liver conditions
GB0712043D0 (en) Compositions
GB0706047D0 (en) Anit-viral compositions
GB0700477D0 (en) Compositions
GB0703964D0 (en) Compositions
GB0713261D0 (en) Compositions
GB0711685D0 (en) Compositions
GB0708492D0 (en) Compositions
GB0723803D0 (en) Compositions